Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer

Trial Profile

The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Apr 2018

At a glance

  • Drugs Apalutamide (Primary) ; LHRH receptor agonists
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Aragon Pharmaceuticals; Johnson & Johnson
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 06 Apr 2018 Planned End Date changed from 31 Jan 2020 to 31 Dec 2019.
    • 06 Apr 2018 Planned primary completion date changed from 31 Jan 2019 to 31 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top